Handelsman David J
ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia.
Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1248-1255. doi: 10.1002/pds.4284. Epub 2017 Aug 23.
To estimate the impact of the first year of new Pharmaceutical Benefits Scheme (PBS) prescribing criteria that dictate eligibility for national health scheme subsidy of testosterone prescribing.
Analysis of cumulative PBS data.
Retrospective analysis of testosterone prescribing from PBS data.
Nil MAIN OUTCOME MEASURES: PBS expenditure analysed by total expenditure, by state, and by product type as well as the age, indication, and prescriber type for new testosterone treatment.
Total PBS expenditure continued to exceed $20 million in 2014 before declining from 2015 with changes that were uniform by state and product type. Prior to 2015, over 80% were for men aged over 40 years of age for low circulating testosterone in the absence of reproductive system disorders ("Low T") initiated by GPs. From 2015, these features were markedly reduced without changing the numbers of new prescriptions for pathological reproductive disorders or specialist initiations.
The short-term impact of 2015 PBS criteria showed highly effective and well-targeted curbing of off-label testosterone prescribing. The findings indicate that the main driver for the recent upsurge in testosterone prescribing was treatment of middle-aged men for "Low T" initiated by GPs.
评估新的药品福利计划（PBS）第一年的处方标准对睾酮处方国家健康计划补贴资格的影响。
对PBS累积数据进行分析。
基于PBS数据对睾酮处方进行回顾性分析。
无
按总支出、州和产品类型分析PBS支出，以及新睾酮治疗的年龄、适应症和开处方者类型。
2014年PBS总支出持续超过2000万美元，之后从2015年开始下降，各州和产品类型的变化较为一致。2015年之前，超过80%的支出用于40岁以上因循环睾酮水平低且无生殖系统疾病（“低睾酮”）而由全科医生启动治疗的男性。从2015年起，这些特征显著减少，而病理性生殖疾病的新处方数量或专科医生启动治疗的数量没有变化。
2015年PBS标准的短期影响显示出对非标签睾酮处方进行了高效且针对性强的管控。研究结果表明，近期睾酮处方激增的主要驱动因素是全科医生对中年男性“低睾酮”的治疗。
